Holen Sie sich die Stockscreener-App
35.35
0.62%
-0.22
Handel nachbörslich:
35.35
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Is Cogent Biosciences Inc. stock a buy for dividend growthDurability and Wear Notes & lightweight options for faster days - ulpravda.ru
A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group - MarketBeat
Aug Ideas: Is Cogent Biosciences Inc. stock a buy for dividend growth2025 Macro Impact & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Cogent Biosciences Inc. stock split again soon2025 Volume Leaders & Reliable Price Breakout Signals - ulpravda.ru
Why Cogent Biosciences Inc. stock is in analyst buy zone2025 EndofYear Setup & Free Technical Confirmation Trade Alerts - ulpravda.ru
How Cogent Biosciences Inc. stock performs during Fed tightening cyclesMarket Movers & Safe Entry Point Identification - ulpravda.ru
Will Cogent Biosciences Inc. stock deliver long term returnsWeekly Risk Summary & Low Volatility Stock Suggestions - ulpravda.ru
Will Cogent Biosciences Inc. stock attract more institutional investorsJuly 2025 Sentiment & Verified Entry Point Detection - ulpravda.ru
Does Cogent Biosciences Inc. stock trade at a discount to peersJuly 2025 Market Mood & Smart Swing Trading Alerts - ulpravda.ru
Does Cogent Biosciences (COGT) Bezuclastinib NDA Redefine Its Competitive Position in Mastocytosis Treatment? - Sahm
Cogent Biosciences announces presentation at the 44th annual J.P. Morgan Healthcare conference - MarketScreener
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COG - GuruFocus
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COGT Stock News - GuruFocus
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences down after market close on insider sales - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Best Biotech Stocks To Follow TodayDecember 31st - MarketBeat
Cogent Biosciences Chief Scientific Officer John Robinson Sells 50% Of Holding - simplywall.st
EV Market: Will Cogent Biosciences Inc stock see PE expansionJuly 2025 News Drivers & Capital Efficiency Focused Ideas - moha.gov.vn
Cogent Biosciences Stock Jumps in 2025 as Executives Sell Shares - Barron's
Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside as Analysts Show Strong Buy Interest - DirectorsTalk Interviews
When Will Cogent Biosciences, Inc. (NASDAQ:COGT) Become Profitable? - 富途牛牛
Voya Investment Management LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing - ts2.tech
Cogent Biosciences (NASDAQ:COGT) Shares Gap Down Following Insider Selling - MarketBeat
Cogent Biosciences Stock Pre-Market (-4.4%): Insider Selling Overwhelms Positive NDA News - Trefis
Wave of High-Level Insider Sales Rocks Cogent Biosciences - TipRanks
Cogent Biosciences presents full SUMMIT results of bezuclastinib - MSN
Insider Sell: Jessica Sachs Sells 82,642 Shares of Cogent Biosci - GuruFocus
Cogent Biosciences (COGT) Shares Drop Following Insider Sales - GuruFocus
Cogent Biosciences stock falls after multiple insider sales By Investing.com - Investing.com UK
Cogent Biosciences stock falls after multiple insider sales - Investing.com
Cogent Biosciences (NASDAQ:COGT) Insider Sells $3,198,245.40 in Stock - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Insider John Edward Robinson Sells 90,000 Shares - MarketBeat
Cogent Biosciences Insider Sold Shares Worth $3,486,600, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $3,198,245, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences Insider Sold Shares Worth $2,978,360, According to a Recent SEC Filing - MarketScreener
Cogent Biosciences Insider Sold Shares Worth $2,515,500, According to a Recent SEC Filing - MarketScreener
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis - The Globe and Mail
Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib - ts2.tech
Cogent Biosciences Submits New Drug Application for Bezuclastinib for Non-Advanced Systemic Mastocytosis - marketscreener.com
Cogent Biosciences (COGT) Advances Bezuclastinib with FDA Submis - GuruFocus
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
JPMorgan Raises Cogent Biosciences (COGT) PT to $67 on Sector Model Update - Insider Monkey
Cogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosis - MSN
Certain Stock Options of Cogent Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 27-DEC-2025. - MarketScreener
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Squarepoint Ops LLC Purchases Shares of 101,518 Cogent Biosciences, Inc. $COGT - MarketBeat
What analysts say about Cogent Biosciences Inc stockMarket Sentiment Surveys & Avoid Market Traps With Pro-Level Warnings - earlytimes.in
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):